Document is current
Any future updates will be listed below
-
Authors
Li, Jin
Xue, Junli
Liu, Tianshu
Feng, Yi
Xu, Nong
Huang, Jianjin
Yin, Yongmei
Zhang, Jun
Mou, Haibo
Shentu, Jiangzhong
Bao, Hanying
Xu, Zusheng
Xu, Zuhong
-
Funding
Funding for this research was provided by:
Shanghai Yingli Pharmaceutical Co., Ltd.
- License Information
-
More Information
Article History
Received: 26 July 2024
Accepted: 5 November 2024
First Online: 13 November 2024
Declarations
:
: Hanying Bao, Zusheng Xu and Zuhong Xu are employees of the Shanghai Yingli Pharmaceutical Co., Ltd., and the other authors declare that no conflict interests exist.
: The study was conducted with the approval of independent ethics committees or institutional review boards of all the study centers and in accordance with the principles of the Declaration of Helsinki, International Conference on Harmonization-Good Clinical Practice, and other applicable regulatory requirements. Institutional review board approval was obtained from the ethical committee of the East Hospital Affiliated to Tongji University. All patients involved in the study provided written informed consent. The study was registered at clinicaltrials.gov with the identifier NCT04049929 (A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors).
